Serina Therapeutics, Inc. - 8-K Filing

Serina Therapeutics advances SER-252 to Cohort 2 in Phase 1b Parkinson's study after positive blinded review of Cohort 1 data (Items: 8.01 Other Items)

SEC EDGAR ·

Tickers: $SER

Read the full article at SEC EDGAR

More Regulatory news